Sparks commentary - Mendus

Healthcare

Sparks - Mendus

More on this equity
Mendus_resized
Mendus (OMX: IMMU) reports manufacturing milestone for vididencel
Published by Arron Aatkar, PhD

Mendus has successfully established good manufacturing practice (GMP) production of vididencel, the company’s lead off-the-shelf cancer vaccine, marking an important milestone for the clinical development of the candidate. This was conducted in accordance with the company’s manufacturing alliance with NorthX Biologics, a leading contract development and manufacturing organisation based in Sweden, established in 2023. Manufacturing is highly important for the development of cell therapies and, with this in place, Mendus is now well positioned to execute its go-to-market approaches in acute myeloid leukaemia and chronic myeloid leukaemia, following its renewed strategy.

Latest

Consumer | Comment

Topps Tiles (LSE: TPT) announces appointment of new CFO

Healthcare | Comment

Herantis Pharma (HEL: HRTIS) – a step closer to Phase II

Investment Companies | Comment

The Biotech Growth Trust (BIOG) reported encouraging H126 results

TMT | Comment

Nanoco (LSE:NANO) settles LG litigation for $5m